Sublime

ethical implications and how to instrument the product to track outcomes.

“Uncle Danny, I don’t know. I’m mad all the time.” Dr. Amen asked if anyone was hurting him or teasing him or touching him inappropriately, and he said no. So Dr. Amen scanned his nephew’s brain and found a cyst the size of a golf ball occupying his left temporal lobe. His nephew was actually missing the space in his scan where his left temporal lo

Hubbard was referring to the agency’s MK-Ultra research program, which since 1953 had been trying to figure out whether LSD could be used as a nonlethal weapon of war (by, say, dumping it in an adversary’s water supply), a truth serum in interrogations, a means of mind control,* or a dirty trick to play on unfriendly foreign leaders, causing them t

examined polygamy, not as a doctrine but as a social policy.

(Sasha Shulgin, who died in 2014, was a brilliant chemist who held a DEA license allowing him to synthesize novel psychedelic compounds, which he did in prodigious numbers. He also was the first to synthesize MDMA since it had been patented by Merck in 1912 and forgotten. Recognizing its psychoactive properties, he introduced the so-called empathog

“What is turned on here is exactly what turns on while people feel pain.” The operative word is while. She goes on, “A person stops using methamphetamine, and this is awaiting them.” Clinicians who work with meth addicts already know that addicts are often depressed, argumentative, anxious, and unwilling to engage in treatment—exactly like Nic—but